Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P

Journal of Immunology

Volumn 179, Issue 6, 2007, Pages 4035-4044

  Pilling, Darrell ^a   Roife, David ^a   Wang, Min ^b   Ronkainen, Sanna D ^a   Crawford, Jeff R ^a   Travis, Elizabeth L ^b   Gomer, Richard H ^a  

^a RICE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; COLLAGEN; HEMOGLOBIN; SERUM AMYLOID P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL INFILTRATION; CONTROLLED STUDY; DRUG ACTIVITY; HEMOGLOBIN BLOOD LEVEL; LEUKOCYTE; LUNG FIBROSIS; MALE; MOUSE; NONHUMAN; OXYGEN SATURATION; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME; TREATMENT RESPONSE; ANIMAL; C57BL MOUSE; CELL COUNT; CELL LINE; CELL MOTION; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; ENDOTRACHEAL INTUBATION; FIBROBLAST; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; PATHOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; BLEOMYCIN; CELL COUNT; CELL LINE; CELL MOVEMENT; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FIBROBLASTS; HUMANS; INJECTIONS, INTRAPERITONEAL; INTUBATION, INTRATRACHEAL; LEUKOCYTES; MALE; MICE; MICE, INBRED C57BL; PULMONARY FIBROSIS; RATS; RATS, SPRAGUE-DAWLEY; SERUM AMYLOID P-COMPONENT; TIME FACTORS;

EID: 35748946038     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.6.4035     Document Type: Article

References (72)

1. Crouch, E. 1990. Pathobiology of pulmonary fibrosis. Am. J. Physiol. 259: L159-L184.
2. Abid, S. H., V. Malhotra, and M. C. Perry. 2001. Radiation-induced and chemotherapy-induced pulmonary injury. Curr. Opin. Oncol. 13: 242-248.
3. Davies, D. E., J. Wicks, R. M. Powell, S. M. Puddicombe, and S. T. Holgate. 2003. Airway remodeling in asthma: new insights. J. Allergy Clin. Immunol. 111: 215-225.
4. Perez, A., R. M. Rogers, and J. H. Dauber. 2003. The prognosis of idiopathic pulmonary fibrosis. Am. J. Physiol. 29: S19-S26.
5. Thannickal, V. J., G. B. Toews, E. S. White, J. P. Lynch III, and F. J. Martinez. 2004. Mechanisms of pulmonary fibrosis. Annu. Rev. Med. 55: 395-417.
6. Walter, N., H. R. Collard, and T. E. King, Jr. 2006. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc. Am. Thorac. Soc. 3: 330-338.
7. Chua, F., J. Gauldie, and G. J. Laurent. 2005. Pulmonary fibrosis: searching for model answers. Am. J. Respir. Cell Mol. Biol. 33: 9-13.
8. Phan, S. H., R. S. Thrall, and P. A. Ward. 1980. Bleomycin-induced pulmonary fibrosis in rats: biochemical demonstration of increased rate of collagen synthesis. Am. Rev. Respir. Dis. 121: 501-506.
9. Smith, R. E., R. M. Strieter, K. Zhang, S. H. Phan, T. J. Standiford, N. W. Lukacs, and S. L. Kunkel. 1995. A role for C-C chemokines in fibrotic lung disease. J. Leukocyte Biol. 57: 782-787.
10. Phan, S. H. 2003. Fibroblast phenotypes in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 29: S87-S92.
11. Quan, T. E., S. Cowper, S.-P. Wu, L. K. Bockenstedt, and R. Bucala. 2004. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int. J. Biochem. Cell Biol. 36: 598-606.
12. Phillips, R. J., M. D. Burdick, K. Hong, M. A. Lutz, L. A. Murray, Y. Y. Xue, J. A. Belperio, M. P. Keane, and R. M. Strieter. 2004. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J. Clin. Invest. 114: 438-446.
13. Bucala, R., L. A. Spiegel, J. Chesney, M. Hogan, and A. Cerami. 1994. Circulating fibrocytes define a new leukocyte subpopulation that mediates tissue repair. Mol. Med. 1: 71-81.
14. Abe, R., S. C. Donnelly, T. Peng, R. Bucala, and C. N. Metz. 2001. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J. Immunol. 166: 7556-7562.
15. Pilling, D., C. D. Buckley, M. Salmon, and R. H. Gomer. 2003. Inhibition of fibrocyte differentiation by serum amyloid P. J. Immunol. 17: 5537-5546.
16. Yang, L., P. G. Scott, J. Giuffre, H. A. Shankowsky, A. Ghahary, and E. E. Tredget. 2002. Peripheral blood fibrocytes from burn patients: identification and quantification of fibrocytes in adherent cells cultured from peripheral blood mononuclear cells. Lab. Invest. 82: 1183-1192.
17. Hashimoto, N., H. Jin, T. Liu, S. W. Chensue, and S. H. Phan. 2004. Bone marrow-derived progenitor cells in pulmonary fibrosis. J. Clin. Invest. 113: 243-252.
18. Moore, B. B., J. E. Kolodsick, V. J. Thannickal, K. Cooke, T. A. Moore, C. Hogaboam, C. A. Wilke, and G. B. Toews. 2005. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am. J. Pathol. 166: 675-684.
19. Moore, B. B., L. Murray, A. Das, C. A. Wilke, A. B. Herrygers, and G. B. Toews. 2006. The role of CCL12 in the recruitment of fibrocytes and lung fibrosis. Am. J. Respir. Cell Mol. Biol. 35: 175-181.
20. Pilling, D., N. M. Tucker, and R. H. Gomer. 2006. Aggregated IgG inhibits the differentiation of human fibrocytes. J. Leukocyte Biol. 79: 1242-1251.
21. Haudek, S. B., Y. Xia, P. Huebener, J. M. Lee, S. Carlson, J. R. Crawford, D. Pilling, R. H. Gomer, J. Trial, N. G. Frangogiannis, and M. L. Entman. 2006. Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice. Proc. Natl. Acad. Sci.USA 103: 18284-18289.
22. Pepys, M. B. 1999. Serum amyloid P component (not serum amyloid protein). Nat. Med. 5: 852-853.
23. Steel, D. M., and A. S. Whitehead. 1994. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol. Today 15: 81-88.
24. Hutchinson, W. L., E. Hohenester, and M. B. Pepys. 2000. Human serum amyloid P component is a single uncomplexed pentamer in whole serum. Mol. Med. 6: 482-493.
25. Mold, C., H. D. Gresham, and T. W. Du Clos. 2001. Serum amyloid P component and C-reactive protein mediate phagocytosis through murine FcγRs. J. Immunol. 166: 1200-1205.
26. Bharadwaj, D., C. Mold, E. Markham, and T. W. Du Clos. 2001. Serum amyloid P component binds to Fcγ receptors and opsonizes particles for phagocytosis. J. Immunol. 166: 6735-6741.
27. Mortensen, R. F., and W. Zhong. 2000. Regulation of phagocytic leukocyte activities by C-reactive protein. J. Leukocyte Biol. 67: 495-500.
28. Bodman-Smith, K. B., A. J. Melendez, I. Campbell, P. T. Harrison, J. M. Allen, and J. G. Raynes. 2002. C-reactive protein-mediated phagocytosis and phospholipase D signalling through the high-affinity receptor for immunoglobulin G (FcγRI). Immunology 107: 252-260.
29. Pepys, M. B., M. Baltz, K. Gomer, A. J. Davies, and M. Doenhoff. 1979. Serum amyloid P-component is an acute-phase reactant in the mouse. Nature 278: 259-261.
30. Noursadeghi, M., M. C. Bickerstaff, J. R. Gallimore, J. Herbert, J. Cohen, and M. B. Pepys. 2000. Role of serum amyloid P component in bacterial infection: protection of the host or protection of the pathogen. Proc. Natl. Acad. Sci. USA 97: 14584-14589.
31. Pepys, M. B., J. Herbert, W. L. Hutchinson, G. A. Tennent, H. J. Lachmann, J. R. Gallimore, L. B. Lovat, T. Bartfai, A. Alanine, C. Hertel, et al. 2002. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417: 254-259.
32. Armstrong, G. D., G. L. Mulvey, P. Marcato, T. P. Griener, M. C. Kahan, G. A. Tennent, C. A. Sabin, H. Chart, and M. B. Pepys. 2006. Human serum amyloid P component protects against Escherichia coli O157:H7 Shiga toxin 2 in vivo: therapeutic implications for hemolytic-uremic syndrome. J. Infect. Dis. 193: 1120-1124.
33. Hawkins, P. N., G. A. Tennent, P. Woo, and M. B. Pepys. 1991. Studies in vivo and in vitro of serum amyloid P component in normals and in a patient with AA amyloidosis. Clin. Exp. Immunol. 84: 308-316.
34. Pepys, M. B. 1979. Isolation of serum amyloid P-component (protein SAP) in the mouse. Immunology 37: 637-641.
35. De Beer, F. C., M. L. Baltz, E. A. Munn, A. Feinstein, J. Taylor, C. Bruton, J. R. Clamp, and M. B. Pepys. 1982. Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology 45: 55-70.
36. Underwood, D. C., R. R. Osborn, S. Bochnowicz, E. F. Webb, D. J. Rieman, J. C. Lee, A. M. Romanic, J. L. Adams, D. W. P. Hay, and D. E. Griswold. 2000. SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung. Am. J. Physiol. 279: L895-L902.
37. Griselli, M., J. Herbert, W. L. Hutchinson, K. M. Taylor, M. Sohail, T. Krausz, and M. B. Pepys. 1999. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J. Exp. Med. 190: 1733-1740.
38. Lopez-De Leon, A., and M. Rojkind. 1985. A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J. Histochem. Cytochem. 33: 737-743.
39. Joseph, J., L. Joseph, N. S. Shekhawat, S. Devi, J. Wang, R. B. Melchert, M. Hauer-Jensen, and R. H. Kennedy. 2003. Hyperhomocysteinemia leads to pathological ventricular hypertrophy in normotensive rats. Am. J. Physiol. 285: H679-H686.
40. Pilling, D., A. N. Akbar, J. Girdlestone, C. H. Orteu, N. J. Borthwick, N. Amft, D. Scheel-Toellner, C. D. Buckley, and M. Salmon. 1999. Interferon-β mediates stromal cell rescue of T cells from apoptosis. Eur. J. Immunol. 29: 1041-1050.
41. Buckley, C. D., N. Amft, P. F. Bradfield, D. Pilling, E. Ross, F. Arenzana-Seisdedos, A. Amara, S. J. Curnow, J. M. Lord, D. Scheel-Toellner, and M. Salmon. 2000. Persistent induction of the chemokine receptor CXCR4 by TGF-β1 on synovial T cells contributes to their accumulation within the rheumatoid synovium. J. Immunol. 165: 3423-3429.
42. Baschong, W., R. Suetterlin, and R. H. Laeng. 2001. Control of autofluorescence of archival formaldehyde-fixed, paraffin-embedded tissue in confocal laser scanning micros (CLSM). J. Histochem. Cytochem. 49: 1565-1572.
43. Orteu, C. H., L. W. Poulter, M. H. A. Rustin, C. A. Sabin, M. Salmon, and A. N. Akbar. 1998. The role of apoptosis in the resolution of T cell mediated cutaneous inflammation. J. Immunol. 161: 1619-1629.
44. Kumar, R. K. 1989. Quantitative immunohistologic assessment of lymphocyte populations in the pulmonary inflammatory response to intratracheal silica. Am. J. Pathol. 135: 605-614.
45. Dolhnikoff, M., T. Mauad, and M. S. Ludwig. 1999. Extracellular matrix and oscillatory mechanics of rat lung parenchyma in bleomycin-induced fibrosis. Am. J. Respir. Crit. Care Med. 160: 1750-1757.
46. Kumar, R. K., C. Herbert, D. C. Webb, L. Li, and P. S. Foster. 2004. Effects of anticytokine therapy in a mouse model of chronic asthma. Am. J. Respir. Crit. Care Med. 170: 1043-1048.
47. Kumar, R. K. 2005. Morphological methods for assessment of fibrosis. Methods Mol. Med. 117: 179-188.
48. Haston, C. K., C. I. Amos, T. M. King, and E. L. Travis. 1996. Inheritance of susceptibility to bleomycin-induced pulmonary fibrosis in the mouse. Cancer Res. 56: 2596-2601.
49. Haston, C. K., X. Zhou, L. Gumbiner-Russo, R. Irani, R. Dejournett, X. Gu, M. Weil, C. I. Amos, and E. L. Travis. 2002. Universal and radiation-specific loci influence murine susceptibility to radiation-induced pulmonary fibrosis. Cancer Res. 62: 3782-3788.
50. Du, M., R. A. Irani, D. N. Stivers, S. J. Lee, and E. L. Travis. 2004. H2-Ea deficiency is a risk factor for bleomycin-induced lung fibrosis in mice. Cancer Res. 64: 6835-6839.
51. Haston, C. K., T. G. Tomko, N. Godin, L. Kerckhoff, and M. T. Hallett. 2005. Murine candidate bleomycin induced pulmonary fibrosis susceptibility genes identified by gene expression and sequence analysis of linkage regions. J. Med. Genet. 42: 464-473.
52. Cavanaugh, D., E. L. Travis, R. E. Price, G. Gladish, R. A. White, M. Wang, and D. D. Cody. 2006. Quantification of bleomycin-induced murine lung damage in vivo with micro-computed tomography. Acad. Radiol. 13: 1505-1512.
53. Broughton, A., J. E. Strong, P. Y. Holoye, and C. W. Bedrossian. 1977. Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay. Cancer 40: 2772-2778.
54. Hall, S. W., J. E. Strong, A. Broughton, M. L. Frazier, and R. S. Benjamin. 1982. Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother. Pharmacol. 9: 22-25.
55. Lazo, J. S., and E. T. Pham. 1984. Pulmonary fate of [3H]bleomycin A2 in mice. J. Pharmacol. Exp. Ther. 228: 13-18.
56. Giri, S. N. 1986. Pharmacokinetics, subcellular distribution, and covalent binding of [3H]bleomycin in hamsters after intratracheal administration. Exp. Mol. Pathol. 45: 207-220.
57. Zhang, H. Y., M. Gharaee-Kermani, K. Zhang, S. Karmiol, and S. H. Phan. 1996. Lung fibroblast α-smooth muscle actin expression and contractile phenotype in bleomycin-induced pulmonary fibrosis. Am. J. Pathol. 148: 527-537.
58. Keane, M. P., J. A. Belperio, T. A. Moore, B. B. Moore, D. A. Arenberg, R. E. Smith, M. D. Burdick, S. L. Kunkel, and R. M. Strieter. 1999. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J. Immunol. 162: 5511-5518.
59. Hagimoto, N., K. Kuwano, Y. Nomoto, R. Kunitake, and N. Hara. 1997. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am. J. Respir. Cell Mol. Biol. 16: 91-101.
60. Ortiz, L. A., K. Moroz, J. Y. Liu, G. W. Hoyle, T. Hammond, R. F. Hamilton, A. Holian, W. Banks, A. R. Brody, and M. Friedman. 1998. Alveolar macrophage apoptosis and TNF-α, but not p53, expression correlate with murine response to bleomycin. Am. J. Physiol. 275: L1208-L1218.
61. Wang, R., O. Ibarra-Sunga, L. Verlinski, R. Pick, and B. D. Uhal. 2000. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am. J. Physiol. 279: L143-L151.
62. Mortensen, R. F., K. Beisel, N. J. Zeleznik, and P. T. Le. 1983. Acute-phase reactants of mice. II. Strain dependence of serum amyloid P-component (SAP) levels and response to inflammation. J. Immunol. 130: 885-889.
63. Chesney, J., C. Metz, A. B. Stavitsky, M. Bacher, and R. Bucala. 1998. Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes. J. Immunol. 160: 419-425.
64. Savill, J., I. Dransfield, C. Gregory, and C. Haslett. 2002. A blast from the past: clearance of apoptotic cells regulates immune responses. Nat. Rev. Immunol. 2: 965-975.
65. Mori, L., A. Bellini, M. A. Stacey, M. Schmidt, and S. Mattoli. 2005. Fibrocytes contribute to the myofibroblast population in wounded skin and originate from the bone marrow. Exp. Cell Res. 304: 81-90.
66. Yang, L., P. G. Scott, C. Dodd, A. Medina, H. Jiao, H. A. Shankowsky, A. Ghahary, and E. E. Tredget. 2005. Identification of fibrocytes in postburn hypertrophic scar. Wound Repair Regeneration 13: 398-404.
67. Schmidt, M., G. Sun, M. A. Stacey, L. Mori, and S. Mattoli. 2003. Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma. J. Immunol. 171: 380-389.
68. Direkze, N. C., S. J. Forbes, M. Brittan, T. Hunt, R. Jeffery, S. L. Preston, R. Poulsom, K. Hodivala-Dilke, M. R. Alison, and N. A. Wright. 2003. Multiple organ engraftment by bone-marrow-derived myofibroblasts and fibroblasts in bone-marrow-transplanted mice. Stem Cells 21: 514-520.
69. Epperly, M. W., H. Guo, J. E. Gretton, and J. S. Greenberger. 2003. Bone marrow origin of myofibroblasts in irradiation pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 29: 213-224.
70. Kisseleva, T., H. Uchinami, N. Feirt, O. Quintana-Bustamante, J. C. Segovia, R. F. Schwabe, and D. A. Brenner. 2006. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J. Hepatol. 45: 429-438.
71. Varcoe, R. L., M. Mikhail, A. K. Guiffre, G. Pennings, M. Vicaretti, W. J. Hawthorne, J. P. Fletcher, and H. J. Medbury. 2006. The role of the fibrocyte in intimal hyperplasia. Thromb. Haemostasis 4: 1125-1133.
72. Sakai, N., T. Wada, H. Yokoyama, M. Lipp, S. Ueha, K. Matsushima, and S. Kaneko. 2006. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc. Natl. Acad. Sci. USA 103: 14098-14103.